TINJAUAN SISTEMATIS EFEKTIFITAS DAN KEAMANAN OBAT FONDAPARINUX TERHADAP PASIEN COVID-19
Keywords:
Fondaparinux, Antikoagulan, Koagulapati, COVID-19, Fondaparinux, Antikoagulan, Koagulapati, COVID-19Abstract
Fondaparinux, yang secara kimiawi berhubungan dengan heparin berbobot molekul rendah, berpotensi digunakan dalam terapi antikoagulan untuk pasien COVID-19. Tinjauan sistematis ini dilakukan untuk menilai efektifitas dan keamanan terapi fondaparinux terhadap pasien COVID-19. Penelitian ini dilaporkan dengan mengikuti pedoman Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA). Kami menggunakan mesin pencari PubMed dan Embase untuk mencari artikel yang melaporkan efektivitas dan keamanan fondaparinux pada pasien COVID-19 yang diterbitkan hingga September 2022. Protokol penelitian ini telah terdaftar di PROSPERO (CRD42021237286). Data hasil penelitian disajikan secara deskriptif. Diantara 355 artikel yang teridentifikasi dari mesin pencarian PubMed dan Embase dan satu artikel dari penelusuran manual, ada lima artikel yang memenuhi syarat yang terdiri dari empat studi kohort retrospektif dan satu artikel studi laporan kasus. Semua artikel menyatakan bahwa fondaparinux (2,5 mg/hari) dapat memperbaiki kondisi klinis pasien COVID-19, sebanding dengan antikoagulan lain seperti Unfractioned Heparin (UFH) dan Enoxaparin, dalam mengatasi resiko koagulapati, resiko Venous Thromboembolism (VTE), meningkatkan kualitas pernapasan pasien, menurunkan nilai D-dimer, dan resiko kematian. Dari keseluruhan laporan, fondaparinux juga ditemukan sebagai obat dengan keamanan yang baik. Oleh karena itu, dapat disimpulkan bahwa fondaparinux adalah kandidat terapi antikoagulan yang menjanjikan untuk pasien COVID-19. Namun, penelitian lebih lanjut dengan metodologi lebih baik masih dibutuhkan untuk memastikan potensi penggunaan fondaparinux sebagai antikoagulan pada COVID-19.References
WHO. Transmisi SARS-CoV-2: implikasi terhadap kewaspadaan pencegahan infeksi. Pernyataan keilmuan. 2020;9.
2. WHO. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2023. Available from: https://covid19.who.int/
3. Sunggoro AJ, Purwanto I, Hasan M. Trombosis pada corona virus disease (COVID-19). Jurnal Kedokteran Syiah Kuala. 2020;20(3).
4. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. Journal of the American college of cardiology. 2020;75(23):2950–73.
5. Rusdiana T, Akbar R. Perkembangan terkini terapi Antikoagulan pada pasien Covid-19 bergejala berat. Jurnal Sains Farmasi & Klinis. 2020;7(3):244–50.
6. Arepally GM. Heparin-induced thrombocytopenia. Blood, The Journal of the American Society of Hematology. 2017;129(21):2864–72.
7. Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgraduate medical journal. 2007;83(983):575–82.
8. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4(1):1–9.
9. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic reviews. 2016;5(1):1–10.
10. McHugh ML. Interrater reliability: the kappa statistic. Biochemia medica. 2012;22(3):276–82.
11. Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Systematic reviews of effectiveness. Joanna Briggs Institute Reviewer’s Manual Adelaide: Joanna Briggs Institute. 2017.
12. Ikatan Dokter Indonesia. Rekomendasi IDI, Pemberian Antikoagulan Profilaksis Pada Pasien Covid-19 yang Dirawat di Rumah Sakit. Ikatan Dokter Indonesia. 2020.
13. Chaerub J. Terapi Antikoagulan pada COVID-19. Cermin Dunia Kedokteran. 2021;48(6):340–2.
14. Russo V, Cardillo G, Viggiano GV, Mangiacapra S, Cavalli A, Fontanella A, et al. Fondaparinux use in patients with COVID-19: a preliminary multicenter real-world experience. Journal of Cardiovascular Pharmacology. 2020;76(4):369–71.
15. Fachri M, Hatta M, Tarigan SNNA, Akaputra R, Dwiyanti R, Syukri A, et al. Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study. Annals of Medicine and Surgery. 2022.
16. Scarvelis D, Wells PS. Diagnosis and treatment of deep-vein thrombosis. Cmaj. 2006;175(9):1087–92.
17. Rachmi DA, Mulia EPB, Nugroho J. Possible mechanism and current recommendation of thromboembolism in COVID-19. Open Access Macedonian Journal of Medical Sciences. 2020;8(T1):66–74.
18. Shah S, Shah K, Patel SB, Patel FS, Osman M, Velagapudi P, et al. Elevated D-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis. Cardiology in review. 2020;
19. Russo V, Cardillo G, Viggiano GV, Mangiacapra S, Cavalli A, Fontanella A, et al. Thromboprofilaxys with fondaparinux vs. enoxaparin in hospitalized COVID-19 patients: a multicenter Italian observational study. Frontiers in medicine. 2020;7:569567.
20. Azizah NF, Faizah RN, Prihantini IK, Romadhian IG, others. Efektifitas Penggunaan Enoxaparin dan Fondaparinux Sebagai Antikoagulan Pada Pasien Covid-19 di RSUD Sidoarjo. Majalah Farmaseutik. 2022;18(1):57–64.
21. Rianda RV, Subkhan M, Pradana AD, Fatimah FN, Rianda RA, Airlangga MP, et al. The Challenging Anticoagulant Therapy in COVID19 Patient with Associated Coagulopathy. Acta Medica Indonesiana. 2021;53(3):308–14.
22. Soliman S, Ghaly M. Ischemic stroke and bilateral pulmonary embolism in COVID-19: COVID-associated coagulopathy or heparin-induced thrombocytopenia. Journal of Hematology. 2022;11(1):40.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Majalah Farmasi dan Farmakologi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copyright to this article is transferred to Universitas Hasanuddin (UNHAS) if and when the article is accepted for publication. The undersigned hereby transfers all rights in and to the paper including without limitation all copyrights to UNHAS. The undersigned hereby represents and warrants that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required. The undersigned represents that he/she has the power and authority to make and execute this assignment.
We declare that:
- This paper has not been published in the same form elsewhere.
- It will not be submitted anywhere else for publication prior to acceptance/rejection by this Journal.
- A copyright permission is obtained for materials published elsewhere and which require this permission for reproduction.
Furthermore, I/We hereby transfer the unlimited rights of publication of the above-mentioned paper in whole to UNHAS The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline, online) or any other reproductions of similar nature.
The corresponding author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. This agreement is to be signed by at least one of the authors who have obtained the assent of the co-author(s) where applicable. After submission of this agreement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted.
